BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Regulatory Post Marketing Surveillance Study on YAZ
Completed
- Conditions
- ContraceptionPremenstrual SyndromeAcne
- Interventions
- Drug: EE20/DRSP (YAZ, BAY86-5300)
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 770
- Registration Number
- NCT00998257
Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 360
- Registration Number
- NCT00993109
Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
Completed
- Conditions
- Contraception
- Interventions
- Drug: Other combined oral contraceptivesDrug: EE30-DRSP (Yasmin, BAY86-5131)
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 632
- Registration Number
- NCT00988910
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2595
- Registration Number
- NCT00987792
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Phase 3
Completed
- Conditions
- Thyroid Neoplasms
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006)Drug: Placebo
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 417
- Registration Number
- NCT00984282
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Birth Control Patch Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)Drug: Norelgestromin/Ethinylestradiol (EVRA)
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 393
- Registration Number
- NCT00984789
Sinecort Pilot Efficacy Study
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Device: Sinecort creamDrug: Hydrocortison creamOther: Untreated skin
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT00980135
Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)
Phase 3
Completed
- Conditions
- Vasomotor RhinitisSeasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 331
- Registration Number
- NCT00976209
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers
Phase 1
Terminated
- Conditions
- Diagnostic Imaging
- Interventions
- Drug: BAY86-4367
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT00975299
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00973245
© Copyright 2025. All Rights Reserved by MedPath